Abstract:SESSION TITLE: Chest Infections Posters 10 SESSION TYPE: Original Investigation Posters PRESENTED ON: 10/11/2023 12:00 pm - 12:45 pm PURPOSE: Mycobacterium avium complex lung disease (MACLD) is a serious pulmonary infection that can cause lung damage. Patients with refractory MACLD often still test positive for MAC infection after 6 months on guideline-based therapy. There are limited data on treatment patterns and healthcare resource utilization (HCRU) among patients with refractory MACLD in the US. The objective of this study was to assess HCRU among US patients with potentially refractory MACLD treatment patterns. METHODS: A retrospective study was conducted using managed care claims from the IBM® MarketScan® research database (2014.07-2020.06). Treated MACLD patients were those who received diagnosis and subsequent initial therapy of ≥28 days of concurrent macrolide with at least one other antibiotic (ethambutol, rifamycin, aminoglycoside, fluoroquinolone, oxazolidinone, diarylquinoline). The first 6 months of treatment was defined as the baseline regimen and the possible refractory date was the date 6 months after treatment initiation. Among patients treated for ≥18 months, treatment patterns indicating potentially refractory MACLD were defined as adding new drug classes after the 6-month baseline treatment. The proportion of refractory MACLD patients with hospitalizations (all-cause, respiratory-related, and NTMLD-related) was assessed at 6-month intervals for a total of 2 years after treatment initiation. RESULTS: The study identified 87 patients (7.5% of 1164 patients treated for MACLD) who showed potentially refractory treatment patterns during the 12-month period after the possible refractory date. Mean (SD) age at MACLD diagnosis was 62 (13) years; 70% were female. During the baseline period, 16% had gastroesophageal reflux disease; common pulmonary comorbidities included COPD (32%), bronchiectasis (29%), pneumonia (29%) and asthma (21%). All-cause and respiratory-related hospitalization rates were high (17% and 7%) during the 6-month baseline treatment period and continued to increase over the 2-year follow-up period, reaching 22% and 11% in months 19-24 after treatment initiation despite treatment of at least 18 months. Ethambutol and rifamycin were included in the baseline regimens of 85% and 82% of refractory patients, respectively. Fluoroquinolone was the most commonly added drug (by 77% of patients) in the 12-month post-refractory treatment period, followed by aminoglycoside (9%). CONCLUSIONS: Despite treatment of at least 1.5 years, patients with potentially refractory MACLD showed high hospitalization burden which remained high or increased over a 2-year follow-up period after treatment initiation. CLINICAL IMPLICATIONS: The increase in hospitalization burden observed after the 6-month initial treatment highlights the need for treatment monitoring and improved management among patients with refractory MACLD. DISCLOSURES: Employee relationship with Insmed Pharmaceuticals Please note: 4 years Added 03/24/2023 by Mariam Hassan, source=Web Response, value=Salary No relevant relationships by Matthew Lucci No relevant relationships by Bonny Shah Employee relationship with Insmed Incorporated Please note: Mar 2017 to Present by Ping Wang, value=Salary Employee relationship with Insmed Incorporated Please note: Mar 2017 to Present Added 03/23/2023 by Ping Wang, source=Web Response, value=Stocks No relevant relationships by Emily Welch Research relationship with Insmed Please note: 24 months or more by Kevin Winthrop, value=Consultation fees Research relationship with Paratek Please note: 24 months or more by Kevin Winthrop, value=Consulting fees Research relationship with Redhill Biopharma Please note: 24 months or more by Kevin Winthrop, value=Consultation fees Research relationship with AN2 Please note: 24 months or more by Kevin Winthrop, value=Grant/Research Support Consultant relationship with AN2 Please note: 24 months or more by Kevin Winthrop, value=Consulting fee Consultant relationship with Spero Therapeutics Please note: 24 months or more by Kevin Winthrop, value=Consulting fee

Effect of multidrug therapy on the prognosis of Mycobacterium avium complex pulmonary disease

Multiple bacterial culture positivity reflects the severity and prognosis as bronchiectasis in Mycobacterium avium complex pulmonary disease

The role of treatment regimen and duration in treating patients with Mycobacterium avium complex lung disease: a real-world experience and case-control study

Clinical course and risk factors of mortality in Mycobacterium avium complex lung disease without initial treatment

Therapeutic effects of various initial combinations of chemotherapy including clarithromycin against Mycobacterium avium complex pulmonary disease

Treatment outcomes for Mycobacterium avium complex: a systematic review and meta-analysis

Correlation of drug exposure and bacterial susceptibility with treatment response for Mycobacterium avium complex lung disease: protocol for a prospective observational cohort study

Long-term Outcomes of Adjunctive Lung Resection for Nontuberculous Mycobacteria Pulmonary Disease

Preliminary Observations of Veterans Without HIV Who Have Mycobacterium avium Complex Pulmonary Disease

Relationship between clarithromycin MICs and treatment responses in Mycobacterium avium complex pulmonary disease

Impact of Different Subspecies on Disease Progression in Initially Untreated Patients with Mycobacterium Avium Complex Lung Disease

Clinical outcomes of lung transplant recipients with pre‐transplant Mycobacterium avium complex infection

Change of erythrocyte sedimentation rate as prognostic biomarker for Mycobacterium avium complex pulmonary disease through anti-mycobacterial treatment

Clinical characteristics of pulmonary Mycobacterium avium complex disease in patients with interstitial lung disease

Beyond Symptoms: Radiologic identification of asymptomatic Mycobacterium avium complex pulmonary infections

Treatment patterns and health care resource utilization among patients with potentially treatment-refractory mycobacterium avium complex lung disease in the united states

How do I manage disseminated Mycobacterium avium complex disease in people with HIV?

Factors Associated with Treatment Outcome in Patients with Nontuberculous Mycobacterial Pulmonary Disease: A Large Population-Based Retrospective Cohort Study in Shanghai

Single-cell transcriptomics by clinical course of Mycobacterium avium complex pulmonary disease

Effects Of Mycophenolate Mofetil Combined With Corticosteroids For Induction Therapy Of Microscopic Polyangiitis

Significance of changes in cavity after treatment in Mycobacterium avium complex pulmonary disease